{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:41:41Z","timestamp":1777574501973,"version":"3.51.4"},"reference-count":56,"publisher":"SAGE Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2020,10,27]]},"abstract":"<jats:p>Background: Many Alzheimer\u2019s disease patients in clinical practice are on polypharmacy for treatment of comorbidities. Objective: While pharmacokinetic interactions between drugs have been relatively well established with corresponding treatment guidelines, many medications and common genotype variants also affect central brain circuits involved in cognitive trajectory, leading to complex pharmacodynamic interactions and a large variability in clinical trials. Methods: We applied a mechanism-based and ADAS-Cog calibrated Quantitative Systems Pharmacology biophysical model of neuronal circuits relevant for cognition in Alzheimer\u2019s disease, to standard-of-care cholinergic therapy with COMTVal158Met, 5-HTTLPR rs25531, and APOE genotypes and with benzodiazepines, antidepressants, and antipsychotics, all together 9,585 combinations. Results: The model predicts a variability of up to 14 points on ADAS-Cog at baseline (COMTVV 5-HTTLPRss APOE 4\/4 combination is worst) and a four-fold range for the rate of progression. The progression rate is inversely proportional to baseline ADAS-Cog. Antidepressants, benzodiazepines, first-generation more than second generation, and most antipsychotics with the exception of aripiprazole worsen the outcome when added to standard-of-care in mild cases. Low dose second-generation benzodiazepines revert the negative effects of risperidone and olanzapine, but only in mild stages. Non APOE4 carriers with a COMTMM and 5HTTLPRLL are predicted to have the best cognitive performance at baseline but deteriorate somewhat faster over time. However, this effect is significantly modulated by comedications. Conclusion: Once these simulations are validated, the platform can in principle provide optimal treatment guidance in clinical practice at an individual patient level, identify negative pharmacodynamic interactions with novel targets and address protocol amendments in clinical trials.<\/jats:p>","DOI":"10.3233\/jad-200688","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T16:15:16Z","timestamp":1601396116000},"page":"413-424","source":"Crossref","is-referenced-by-count":8,"title":["Simulating the Effects of Common Comedications and Genotypes on Alzheimer\u2019s Cognitive Trajectory Using a Quantitative Systems Pharmacology Approach"],"prefix":"10.1177","volume":"78","author":[{"given":"Hugo","family":"Geerts","sequence":"first","affiliation":[{"name":"Certara-SimCyp \u2013 UK, Berwyn, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athan","family":"Spiros","sequence":"additional","affiliation":[{"name":"In Silico Biosciences, Lexington, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-200688_ref1","first-page":"33","article-title":"Comorbidity and polypharmacy in people with dementia: Insights from a large, population-based cross-sectional analysis of primary care data","volume":"46","author":"Clague","year":"2016","journal-title":"Age Ageing"},{"key":"10.3233\/JAD-200688_ref2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jamainternmed.2014.7663","article-title":"Cumulative use of strong anticholinergics and incident dementia: A prospective cohort study","volume":"175","author":"Gray","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.3233\/JAD-200688_ref3","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/jamaneurol.2016.0580","article-title":"Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults","volume":"73","author":"Risacher","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-200688_ref4","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/gerona\/glv219","article-title":"Medication regimen complexity and number of medications as factors associated with unplanned hospitalizations in older people: A population-based cohort study","volume":"71","author":"Wimmer","year":"2016","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.3233\/JAD-200688_ref5","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1177\/1533317511432734","article-title":"Functional decline associated with polypharmacy and potentially inappropriate medications in community-dwelling older adults with dementia","volume":"26","author":"Lau","year":"2011","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"10.3233\/JAD-200688_ref6","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12888-015-0531-9","article-title":"Drug-induced cerebral glucose metabolism resembling Alzheimer\u2019s Disease: A case study","volume":"15","author":"Riepe","year":"2015","journal-title":"BMC Psychiatry"},{"key":"10.3233\/JAD-200688_ref7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/14737175.2016.1194203","article-title":"Analysis of recent failures of disease modifying therapies in Alzheimer\u2019s disease suggesting a new methodology for future studies","volume":"17","author":"Amanatkar","year":"2017","journal-title":"Expert Rev Neurother"},{"key":"10.3233\/JAD-200688_ref8","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/(SICI)1096-8628(19960920)67:5<468::AID-AJMG5>3.0.CO;2-G","article-title":"Association of codon 108\/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome","volume":"67","author":"Lachman","year":"1996","journal-title":"Am J Med Genet"},{"key":"10.3233\/JAD-200688_ref9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/BF01281159","article-title":"Functional promoter and polyadenylation site mapping of the human serotonin (5-HT) transporter gene","volume":"102","author":"Heils","year":"1995","journal-title":"J Neural Transm Gen Sect"},{"key":"10.3233\/JAD-200688_ref10","doi-asserted-by":"crossref","first-page":"767","DOI":"10.14348\/molcells.2014.0248","article-title":"Apolipoprotein E in synaptic plasticity and Alzheimer\u2019s disease: Potential cellular and molecular mechanisms","volume":"37","author":"Kim","year":"2014","journal-title":"Mol Cells"},{"key":"10.3233\/JAD-200688_ref11","doi-asserted-by":"crossref","first-page":"10186","DOI":"10.1073\/pnas.1609896113","article-title":"Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes","volume":"113","author":"Chung","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-200688_ref12","doi-asserted-by":"crossref","first-page":"15317","DOI":"10.1523\/JNEUROSCI.4026-09.2009","article-title":"ApoE4 Decreases spine density and dendritic complexity in cortical neurons in vivo","volume":"29","author":"Dumanis","year":"2009","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-200688_ref13","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-018-0343-5","article-title":"Impact of amyloid-beta changes on cognitive outcomes in Alzheimer\u2019s disease: Analysis of clinical trials using a quantitative systems pharmacology model","volume":"10","author":"Geerts","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-200688_ref14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/alzrt153","article-title":"Simulations of symptomatic treatments for Alzheimer\u2019s disease: Computational analysis of pathology and mechanisms of drug action","volume":"4","author":"Roberts","year":"2012","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-200688_ref15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4236\/aad.2013.23012","article-title":"Systems pharmacology modeling in neuroscience: Prediction and outcome of PF-04995274, a 5-HT4 partial agonist, in a clinical scopolamine impairment trial","volume":"2","author":"Nicholas","year":"2013","journal-title":"Adv Alzheimer Dis"},{"key":"10.3233\/JAD-200688_ref16","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1177\/0269881118796809","article-title":"Predicting parkinsonism side-effects of antipsychotic polypharmacy prescribed in secondary mental healthcare","volume":"32","author":"Kadra","year":"2018","journal-title":"J Psychopharmacol"},{"key":"10.3233\/JAD-200688_ref17","first-page":"589","article-title":"Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse","volume":"6","author":"Spiros","year":"2010","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.3233\/JAD-200688_ref18","first-page":"53","article-title":"A quantitative way to estimate clinical off-target effects for human membrane brain targets in CNS research and development","volume":"4","author":"Spiros","year":"2012","journal-title":"J Exp Pharmacol"},{"key":"10.3233\/JAD-200688_ref19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nature11691","article-title":"Automated design of ligands to polypharmacological profiles","volume":"492","author":"Besnard","year":"2012","journal-title":"Nature"},{"key":"10.3233\/JAD-200688_ref20","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/ddr.21008","article-title":"A quantitative systems pharmacology computer model for schizophrenia efficacy and extrapyramidal side effects","volume":"73","author":"Spiros","year":"2012","journal-title":"Drug Dev Res"},{"key":"10.3233\/JAD-200688_ref21","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1097\/JGP.0b013e318227f83f","article-title":"Serotonin transporter occupancy and the functional neuroanatomic effects of citalopram in geriatric depression","volume":"19","author":"Smith","year":"2011","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.3233\/JAD-200688_ref22","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.neurobiolaging.2007.02.020","article-title":"PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD","volume":"29","author":"Kadir","year":"2008","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-200688_ref23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1527-3458.2002.tb00237.x","article-title":"Nicotinic cholinergic modulation: Galantamine as a prototype","volume":"8","author":"Woodruff-Pak","year":"2002","journal-title":"CNS Drug Rev"},{"key":"10.3233\/JAD-200688_ref24","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3389\/fphar.2015.00198","article-title":"Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient trial using quantitative systems pharmacology","volume":"6","author":"Geerts","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.3233\/JAD-200688_ref25","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.neurobiolaging.2006.09.020","article-title":"Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine","volume":"29","author":"Darreh-Shori","year":"2008","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-200688_ref26","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1212\/WNL.56.3.408","article-title":"Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET","volume":"56","author":"Shinotoh","year":"2001","journal-title":"Neurology"},{"key":"10.3233\/JAD-200688_ref27","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1038\/psp.2013.12","article-title":"A quantitative system pharmacology computer model for cognitive deficits in schizophrenia","volume":"2","author":"Geerts","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.3233\/JAD-200688_ref28","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/mp.2008.19","article-title":"COMT genotype predicts cortical-limbic D1 receptor availability measured with [11C]NNC112 and PET","volume":"13","author":"Slifstein","year":"2008","journal-title":"Mol Psychiatry"},{"key":"10.3233\/JAD-200688_ref29","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.neuroimage.2012.05.013","article-title":"5-HTTLPR status predictive of neocortical 5-HT4 binding assessed with [(11)C]SB207145 PET in humans","volume":"62","author":"Fisher","year":"2012","journal-title":"Neuroimage"},{"key":"10.3233\/JAD-200688_ref30","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1126\/science.274.5292.1527","article-title":"Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region","volume":"274","author":"Lesch","year":"1996","journal-title":"Science"},{"key":"10.3233\/JAD-200688_ref31","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jama.1995.03520290026015","article-title":"Apolipoprotein E E4 allele and risk of dementia","volume":"273","author":"Roses","year":"1995","journal-title":"JAMA"},{"key":"10.3233\/JAD-200688_ref32","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jalz.2018.08.005","article-title":"Understanding disease progression and improving Alzheimer\u2019s disease clinical trials: Recent highlights from the Alzheimer\u2019s Disease Neuroimaging Initiative","volume":"15","author":"Veitch","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-200688_ref33","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jama.2014.93","article-title":"Effect of citalopram on agitation in Alzheimer disease: The CitAD randomized clinical trial","volume":"311","author":"Porsteinsson","year":"2014","journal-title":"JAMA"},{"key":"10.3233\/JAD-200688_ref34","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3389\/fnbeh.2013.00140","article-title":"Neural basis for the ability of atypical antipsychotic drugs to improve cognition in schizophrenia","volume":"7","author":"Sumiyoshi","year":"2013","journal-title":"Front Behav Neurosci"},{"key":"10.3233\/JAD-200688_ref35","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.neuron.2012.03.023","article-title":"Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment","volume":"74","author":"Bakker","year":"2012","journal-title":"Neuron"},{"key":"10.3233\/JAD-200688_ref36","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.neuron.2010.10.020","article-title":"Transsynaptic progression of amyloid-beta-induced neuronal dysfunction within the entorhinal-hippocampal network","volume":"68","author":"Harris","year":"2010","journal-title":"Neuron"},{"key":"10.3233\/JAD-200688_ref37","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/WNF.0000000000000283","article-title":"De Novo Myoclonic status epilepticus after benzodiazepine withdrawal","volume":"41","author":"Vicente Ferreira Naves","year":"2018","journal-title":"Clij Neuropharmacol"},{"key":"10.3233\/JAD-200688_ref38","first-page":"1457","article-title":"Potential drug-drug interactions in Alzheimer patients with behavioral symptoms","volume":"10","author":"Pasqualetti","year":"2015","journal-title":"Clin Interv Aging"},{"key":"10.3233\/JAD-200688_ref39","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1124\/jpet.102.045773","article-title":"Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors","volume":"305","author":"Samochocki","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.3233\/JAD-200688_ref40","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00213-019-05363-4","article-title":"Evidence for positive allosteric modulation of cognitive-enhancing effects of nicotine in healthy human subjects","volume":"237","author":"Hahn","year":"2019","journal-title":"Psychopharmacology (Berl)"},{"key":"10.3233\/JAD-200688_ref41","doi-asserted-by":"crossref","first-page":"408","DOI":"10.2174\/1567205015666171212094229","article-title":"Catechol-O-methyltransferase, cognition and Alzheimer\u2019s disease","volume":"15","author":"Perkovic","year":"2018","journal-title":"Curr Alzheimer Res"},{"key":"10.3233\/JAD-200688_ref42","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1017\/S1355617702813248","article-title":"What is cognitive reserve? Theory and research application of the reserve concept","volume":"8","author":"Stern","year":"2002","journal-title":"J Int Neuropsychol Soc"},{"key":"10.3233\/JAD-200688_ref43","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.trci.2015.09.001","article-title":"Alzheimer\u2019s disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer\u2019s disease trials of bapineuzumab","volume":"1","author":"Samtani","year":"2015","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.3233\/JAD-200688_ref44","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3233\/JAD-180684","article-title":"Memantine and acetylcholinesterase inhibitor use in Alzheimer\u2019s disease clinical trials: Potential for confounding by indication","volume":"67","author":"Huisa","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-200688_ref45","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/17512433.2018.1501555","article-title":"Use of quantitative clinical pharmacology to improve early clinical development success in neurodegenerative diseases","volume":"11","author":"Geerts","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.3233\/JAD-200688_ref46","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2174\/1871527316666170303144817","article-title":"Clinically relevant drug interactions with anti-Alzheimer\u2019s drugs","volume":"16","author":"Caraci","year":"2017","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.3233\/JAD-200688_ref47","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3233\/JAD-130575","article-title":"Understanding placebo responses in Alzheimer\u2019s disease clinical trials from the literature meta-data and CAMD database","volume":"37","author":"Ito","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-200688_ref48","doi-asserted-by":"crossref","first-page":"13622","DOI":"10.1038\/s41598-019-49656-2","article-title":"Machine learning for comprehensive forecasting of Alzheimer\u2019s disease progression","volume":"9","author":"Fisher","year":"2019","journal-title":"Sci Rep"},{"key":"10.3233\/JAD-200688_ref49","doi-asserted-by":"crossref","first-page":"102199","DOI":"10.1016\/j.nicl.2020.102199","article-title":"Modelling prognostic trajectories of cognitive decline due to Alzheimer\u2019s disease","volume":"26","author":"Giorgio","year":"2020","journal-title":"Neuroimage Clin"},{"key":"10.3233\/JAD-200688_ref50","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0166-19.2019","article-title":"Introduction of tau oligomers into cortical neurons alters action potential dynamics and disrupts synaptic transmission and plasticity","volume":"6","author":"Hill","year":"2019","journal-title":"eNeuro"},{"key":"10.3233\/JAD-200688_ref51","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1474-4422(15)00323-3","article-title":"Transition rates between amyloid and neurodegeneration biomarker states and to dementia: A population-based, longitudinal cohort study","volume":"15","author":"Jack","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-200688_ref52","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/mp.2017.108","article-title":"Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer\u2019s disease dementia","volume":"23","author":"Chiotis","year":"2018","journal-title":"Mol Psychiatry"},{"key":"10.3233\/JAD-200688_ref53","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/alz.12082","article-title":"Learning from amyloid trials in Alzheimer\u2019s disease. A virtual patient analysis using a quantitative systems pharmacology approach","volume":"16","author":"Geerts","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-200688_ref54","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.jalz.2019.07.011","article-title":"Apolipoprotein E epsilon4 allele effects on longitudinal cognitive trajectories are sex and age dependent","volume":"15","author":"Williams","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-200688_ref55","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/jcbfm.2011.11","article-title":"Age and sex effects on 5-HT(4) receptors in the human brain: A [(11)C]SB207145ET study","volume":"31","author":"Madsen","year":"2011","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.3233\/JAD-200688_ref56","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.brainresbull.2015.03.004","article-title":"In vivo evidence for neuroplasticity in older adults","volume":"114","author":"Porto","year":"2015","journal-title":"Brain Res Bull"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-200688","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:09:03Z","timestamp":1777370943000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-200688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,27]]},"references-count":56,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jad-200688","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,27]]}}}